EA200500546A1 - Частицы, покрытые нуклеиновой кислотой - Google Patents
Частицы, покрытые нуклеиновой кислотойInfo
- Publication number
- EA200500546A1 EA200500546A1 EA200500546A EA200500546A EA200500546A1 EA 200500546 A1 EA200500546 A1 EA 200500546A1 EA 200500546 A EA200500546 A EA 200500546A EA 200500546 A EA200500546 A EA 200500546A EA 200500546 A1 EA200500546 A1 EA 200500546A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nucleic acid
- particles
- methods
- particles coated
- delivery
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 7
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229910021645 metal ion Inorganic materials 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
- C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Manufacturing & Machinery (AREA)
- Plant Pathology (AREA)
- Ceramic Engineering (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Предлагаются частицы, которые пригодны для доставки из устройства для опосредуемой частицами доставки. Частицы получают путем осаждения нуклеиновой кислоты на частицах-носителях из инертного металла в присутствии агента, конденсирующего нуклеиновую кислоту, и агента, хелатирующего ионы металла. Также описаны способы получения частиц и способы терапии с применением частиц, включая способы иммунизации нуклеиновой кислотой и генной терапии.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41409702P | 2002-09-27 | 2002-09-27 | |
PCT/GB2003/004202 WO2004028560A1 (en) | 2002-09-27 | 2003-09-29 | Nucleic acid coated particles |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200500546A1 true EA200500546A1 (ru) | 2005-10-27 |
EA010881B1 EA010881B1 (ru) | 2008-12-30 |
Family
ID=32043345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500546A EA010881B1 (ru) | 2002-09-27 | 2003-09-29 | Частицы, покрытые нуклеиновой кислотой |
Country Status (17)
Country | Link |
---|---|
US (1) | US8349364B2 (ru) |
EP (1) | EP1545593A1 (ru) |
JP (1) | JP4791730B2 (ru) |
KR (1) | KR101152561B1 (ru) |
CN (1) | CN100542605C (ru) |
AU (1) | AU2003269213B2 (ru) |
BR (1) | BR0314751A (ru) |
CA (1) | CA2500215C (ru) |
EA (1) | EA010881B1 (ru) |
GB (1) | GB2410497B (ru) |
HK (1) | HK1073797A1 (ru) |
IL (1) | IL167635A (ru) |
MX (1) | MXPA05003222A (ru) |
NZ (1) | NZ539107A (ru) |
PL (1) | PL212483B1 (ru) |
WO (1) | WO2004028560A1 (ru) |
ZA (1) | ZA200503380B (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2513747C (en) | 2003-01-24 | 2017-03-07 | University Of Utah | Methods of predicting mortality risk by determining telomere length |
JP4793956B2 (ja) * | 2005-12-29 | 2011-10-12 | ニチコン株式会社 | アルミニウム電解コンデンサの駆動用電解液、およびこれを用いたアルミニウム電解コンデンサ |
EP2379747B1 (en) | 2008-12-22 | 2013-07-03 | University of Utah Research Foundation | Monochrome multiplex quantitative pcr |
GB0918679D0 (en) | 2009-10-23 | 2009-12-09 | Iqur Ltd | Influenza vaccine |
GB0918782D0 (en) | 2009-10-26 | 2009-12-09 | St Georges Hosp Medical School | A protein as an adjuvant for a vaccine |
CA2914555A1 (en) | 2013-06-06 | 2014-12-11 | David J Rowlands | Single domain antibody display |
CN103736090B (zh) * | 2014-01-27 | 2016-03-02 | 中国医学科学院医学生物学研究所 | 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗 |
WO2016000792A1 (en) * | 2014-07-04 | 2016-01-07 | Biontech Ag | Stabilised formulations of rna |
US9944978B2 (en) | 2014-12-30 | 2018-04-17 | Telomere Diagnostics, Inc. | Multiplex quantitative PCR |
US11326164B2 (en) | 2019-09-29 | 2022-05-10 | Wjwu & Lynn Institute For Stem Cell Research | Trimethylglycylglycerin compositions and their use in developing anti-cancer drugs and RNA vaccines |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5120657A (en) | 1986-12-05 | 1992-06-09 | Agracetus, Inc. | Apparatus for genetic transformation |
KR900007952B1 (ko) | 1988-11-18 | 1990-10-23 | 주식회사 녹십자 | 신규의 한탄바이러스 rok84/105 균주 및 이를 이용한 한탄바이러스 백신의 제조방법 |
US5204253A (en) * | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
CA2051092C (en) * | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
WO1992020809A1 (en) * | 1991-05-15 | 1992-11-26 | Agracetus, Inc. | Method of creating a transformed rice plant |
TW360548B (en) * | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
GB2284208A (en) * | 1993-11-25 | 1995-05-31 | Pna Diagnostics As | Nucleic acid analogues with a chelating functionality for metal ions |
AU674815B2 (en) | 1994-01-21 | 1997-01-09 | Powderject Vaccines, Inc. | Gas driven gene delivery instrument |
GB9416663D0 (en) | 1994-08-17 | 1994-10-12 | Oxford Bioscience Limited | Particle delivery |
AU3703895A (en) | 1994-10-24 | 1996-05-15 | Oxford Biosciences Limited | Particle delivery |
GB9426379D0 (en) | 1994-12-23 | 1995-03-01 | Oxford Biosciences Ltd | Particle delivery |
FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
DE69732029T2 (de) | 1996-04-26 | 2006-02-23 | Merck & Co., Inc. | Dna enthaltende impfstoffen |
IN184589B (ru) | 1996-10-16 | 2000-09-09 | Alza Corp | |
CA2336992A1 (en) | 1998-07-09 | 2000-01-20 | Merck & Co., Inc. | Polynucleotide vaccine formulations |
PT1119630E (pt) * | 1998-11-05 | 2006-05-31 | Powderject Vaccines Inc | Construcoes de acido nucleico para imunizacao genetica |
WO2000072908A1 (en) * | 1999-06-02 | 2000-12-07 | Microheart, Inc. | Devices and methods for delivering a drug |
AU2001252390A1 (en) * | 2000-05-01 | 2001-11-12 | Powderject Vaccines, Inc. | Nucleic acid immunization |
EP1292285A4 (en) * | 2000-06-02 | 2009-07-22 | Eisai Corp North America | SYSTEMS FOR DISPENSING BIOACTIVE AGENTS |
-
2003
- 2003-09-29 CN CNB038251353A patent/CN100542605C/zh not_active Expired - Fee Related
- 2003-09-29 NZ NZ539107A patent/NZ539107A/en not_active IP Right Cessation
- 2003-09-29 WO PCT/GB2003/004202 patent/WO2004028560A1/en active Application Filing
- 2003-09-29 CA CA2500215A patent/CA2500215C/en not_active Expired - Fee Related
- 2003-09-29 BR BR0314751-7A patent/BR0314751A/pt not_active Application Discontinuation
- 2003-09-29 KR KR1020057005212A patent/KR101152561B1/ko not_active IP Right Cessation
- 2003-09-29 MX MXPA05003222A patent/MXPA05003222A/es active IP Right Grant
- 2003-09-29 EP EP03750990A patent/EP1545593A1/en not_active Withdrawn
- 2003-09-29 US US10/529,010 patent/US8349364B2/en not_active Expired - Fee Related
- 2003-09-29 GB GB0508549A patent/GB2410497B/en not_active Expired - Fee Related
- 2003-09-29 AU AU2003269213A patent/AU2003269213B2/en not_active Ceased
- 2003-09-29 EA EA200500546A patent/EA010881B1/ru not_active IP Right Cessation
- 2003-09-29 PL PL375782A patent/PL212483B1/pl unknown
- 2003-09-29 JP JP2004539249A patent/JP4791730B2/ja not_active Expired - Fee Related
-
2005
- 2005-03-24 IL IL167635A patent/IL167635A/en active IP Right Grant
- 2005-04-26 ZA ZA200503380A patent/ZA200503380B/en unknown
- 2005-08-10 HK HK05106899A patent/HK1073797A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP4791730B2 (ja) | 2011-10-12 |
MXPA05003222A (es) | 2005-07-26 |
CA2500215A1 (en) | 2004-04-08 |
GB2410497A (en) | 2005-08-03 |
IL167635A (en) | 2011-07-31 |
EP1545593A1 (en) | 2005-06-29 |
US20060153804A1 (en) | 2006-07-13 |
PL375782A1 (en) | 2005-12-12 |
GB0508549D0 (en) | 2005-06-01 |
US8349364B2 (en) | 2013-01-08 |
CN1694721A (zh) | 2005-11-09 |
PL212483B1 (pl) | 2012-10-31 |
KR101152561B1 (ko) | 2012-06-01 |
BR0314751A (pt) | 2005-07-26 |
GB2410497B (en) | 2006-11-22 |
KR20050070008A (ko) | 2005-07-05 |
HK1073797A1 (en) | 2005-10-21 |
AU2003269213B2 (en) | 2008-11-13 |
NZ539107A (en) | 2008-11-28 |
JP2006503063A (ja) | 2006-01-26 |
WO2004028560A1 (en) | 2004-04-08 |
AU2003269213A1 (en) | 2004-04-19 |
CA2500215C (en) | 2012-02-28 |
EA010881B1 (ru) | 2008-12-30 |
ZA200503380B (en) | 2007-11-28 |
CN100542605C (zh) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200500546A1 (ru) | Частицы, покрытые нуклеиновой кислотой | |
PL397846A1 (pl) | Leczenie zaburzeń związanych z TNFα | |
WO2004076644A3 (en) | A composition for delivering an agent to a target cell and uses thereof | |
AU2001269256A1 (en) | Electrochemical immunoassays using colloidal metal markers | |
WO2003105758A3 (en) | CANCER-RELATED GENE USED AS A TARGET FOR CHEMOTHERAPY | |
WO2003104399A3 (en) | CANCER-RELATED GENE AS A TARGET IN CHEMOTHERAPY | |
WO2003097803A3 (en) | Cancer-linked gene as target for chemotherapy | |
WO2003101400A3 (en) | Cancer-linked gene as target for chemotherapy | |
DK0796345T3 (da) | Apparat til udførelse af magnetisk cyklusreaktion | |
WO2004080418A3 (en) | Nucleic acid compounds for inhibiting angiogenesis and tumor growth | |
HK1073130A1 (en) | Anticancer agents using vero toxin variants | |
WO2004033666A3 (en) | Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases | |
HK1078593A1 (en) | Antibody against a tumor-specific antigen as target | |
WO2008019345A3 (en) | Payer-based account porting to portable value distribution systems and methods | |
WO2007006581A3 (en) | Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression | |
WO2004046182A3 (en) | Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases | |
WO2005019475A3 (en) | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) | |
ATE341567T1 (de) | Verfahren zur anionischen polymerisation von alpha-methylstyrol | |
SG156658A1 (en) | Treatment of diseases | |
MY137442A (en) | Nucleic acid coated particles | |
AU2003292695A1 (en) | Charge particle exposure method, complementarily divided mask used for it, and semiconductor device produced by using the method | |
Cobbs | Improving the quality of end of life care: how? | |
WO2003104401A3 (en) | TARGETED CANCER GENE IN CHEMOTHERAPY | |
WO2003104438A3 (en) | CANCER-RELATED GENES AS CHEMOTHERAPY TARGETS | |
WO2003097802A3 (en) | Cancer-linked gene as target for chemotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |